SAM ALTMAN'S LONGEVITY STARTUP IS UPPING THE DOSE IN AN ALZHEIMER'S DRUG TRIAL AFTER A LACKLUSTER FIRST ROUND - BUSINSIDER

Alzheimer's trial dose increase signals catalyst after lackluster first round.